Disclosed is the use of a sartan e.g. candesartan, eprosartan, irbesartan, losartan, tasosartan, telmisartan, valsartan for the manufacture of a pharmaceutical composition comprising a therapeutically effective amount of sartan for the treatment of chronic kidney disease in cats.